The prognostic value of microRNA-29a in detecting arrhythmias based on 24-hour electrocardiography monitoring in patients with hypertrophic cardiomyopathy
- Авторлар: Vysokikh A.V.1, Kaplunova V.Y.1, Privalova E.V.1
-
Мекемелер:
- I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
- Шығарылым: Том 36, № 11 (2025)
- Беттер: 88-91
- Бөлім: From Practice
- URL: https://bakhtiniada.ru/0236-3054/article/view/362949
- DOI: https://doi.org/10.29296/25877305-2025-11-15
- ID: 362949
Дәйексөз келтіру
Аннотация
Objective. To assess the prognostic value of circulating microRNA-29a expression levels in relation to cardiac arrhythmias detected by 24-hour (Holter) ECG monitoring in patients with hypertrophic cardiomyopathy (HCM).
Materials and methods. The study included 41 patients with a verified diagnosis of HCM (21 men, 20 women), with a mean age of 57.2±14.2 years. All patients underwent 24-hour ECG monitoring. The expression level of microRNA-29a in plasma was measured using RT-qPCR. The Mann–Whitney U test was used for statistical analysis (p < 0.05).
Results. In patients with arrhythmias, the level of microRNA-29a was significantly lower compared to those without arrhythmias (0.206 vs. 0.433; p = 0.0015). No statistically significant associations were found between miR-29a expression and conduction disturbances.
Conclusion. Reduced expression of microRNA-29a may be associated with an increased risk of arrhythmias in patients with HCM. This epigenetic marker could serve as a valuable addition to existing risk stratification tools and warrants further investigation in larger patient cohorts.
Авторлар туралы
A. Vysokikh
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Хат алмасуға жауапты Автор.
Email: andvusokikh@gmail.com
ORCID iD: 0009-0005-6825-3383
SPIN-код: 7298-1353
Ресей, Moscow
V. Kaplunova
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Email: andvusokikh@gmail.com
ORCID iD: 0000-0002-5864-0938
SPIN-код: 5326-7363
Professor, MD
Ресей, MoscowE. Privalova
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Email: andvusokikh@gmail.com
ORCID iD: 0000-0002-9908-9476
Professor, MD
Ресей, MoscowӘдебиет тізімі
- Клинические рекомендации по гипертрофической кардиомиопатии, 2025 [Clinical Guidelines for Hypertrophic Cardiomyopathy, 2025 (in Russ.)].
- Maron B.J., Ommen S.R., Semsarian C. et al. Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. J Am Coll Cardiol. 2014; 64 (1): 83–99. doi: 10.1016/j.jacc.2014.05.003
- O'Mahony C., Jichi F., Pavlou M. et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (ESC Risk Model). Eur Heart J. 2014; 35 (30): 2010–20. doi: 10.1093/eurheartj/eht439
- Ommen S.R., Mital S., Burke M.A. et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy. Circulation. 2020; 142 (25): e558-e631. doi: 10.1161/CIR.0000000000000937
- Шакарьянц Г.А., Кожевникова М.В., Каплунова В.Ю. и др. Взгляд на гипертрофию миокарда с позиции транскриптомики и метаболомики. Кардиология. 2020; 60 (4): 120–9 [Shakaryants G.A., Kozhevnikova M.V., Kaplunova V.Yu. et al. Focus on the Myocardial Hypertrophy from the Perspective of Transcriptomics and Metabolomics. Kardiologiia. 2020; 60 (4): 120–9 (in Russ.)]. doi: 10.18087/cardio.2020.4.n1063
- Roncarati R., Anselmi C.V., Losi M.A. et al. Circulating miR-29a, among other up-regulated microRNAs, is the only biomarker for both hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2014; 63 (9): 920–7. doi: 10.1016/j.jacc.2013.09.041
- Rowin E.J., Hausvater A., Link M.S. et al. Clinical profile and consequences of atrial fibrillation in hypertrophic cardiomyopathy. Circulation. 2017; 136 (25): 2420–36. doi: 10.1161/CIRCULATIONAHA.117.029267
- Yang H. et al. Age-related atrial fibrillation in patients with hypertrophic cardiomyopathy. J Am Heart Assoc. 2014; 3 (6): e001002.
- Zhao Y., Yuan Y., Qiu C. Underexpression of CACNA1C Caused by Overexpression of miR-29a-3p in Atrial Fibrillation. Med Sci Monit. 2016; 22: 1975–81. doi: 10.12659/msm.896191
- Sassi Y., Avramopoulos P., Ramanujam D. et al. Cardiac myocyte miR-29 promotes pathological remodeling of the heart by activating Wnt signaling. Nat Commun. 2017; 8 (1): 1614. doi: 10.1038/s41467-017-01737-4
- Zhang X., McLendon J.M., Peck B.D. et al. Modulation of miR-29 influences myocardial compliance likely through coordinated regulation of calcium handling and extracellular matrix. Mol Ther Nucleic Acids. 2023; 34: 102081. doi: 10.1016/j.omtn.2023.102081
- Balan A.I., Scridon A. MicroRNAs in atrial fibrillation – have we discovered the missing link? Front Pharmacol. 2025; 16: 1535621. doi: 10.3389/fphar.2025.1535621
Қосымша файлдар
